This analysis examines the recent growth of Medicare Advantage as a share of hospital inpatient days. Medicare Advantage rose from 13% to 23% of all inpatient days from 2015 to 2022, although there was wide variation among hospitals.
Category: Kaiser Family Foundation
Supreme Court Decision Limiting the Authority of Federal Agencies Could Have Far-Reaching Impacts for Health Policy
On June 20, 2024, the U.S. Supreme Court overturned a longstanding legal precedent that required federal courts to defer to reasonable agency interpretation when statutes are ambiguous. The decision will shift many policy decisions from federal agencie…
Compare the Candidates on Health Care Policy
The side-by-side comparison tool provides a quick overview of former President Trump’s and Vice President Harris’ records, positions, public statements, and proposed policies on a range of key health care topics.
Compare the Presidential Candidates’ Health Care Records and Positions
The side-by-side comparison tool provides a quick overview of former President Trump’s and President Biden’s records, positions, public statements, and proposed policies on a range of key health care topics.
The Health Wonk Shop: What’s Behind the Buzz about Site-Neutral Payments?
A panel of experts joined Larry Levitt, KFF’s executive vice president for health policy, for a discussion on the concept of site-neutral payments, including why it has become an issue for policymakers and private payers like insurers and employers, ho…
Five Things to Know About Medicare Site-Neutral Payment Reforms
This brief examines key facts around proposals to align Medicare payments for outpatient services across care settings, otherwise known as “site-neutral payment reforms.”
The Facts About the $35 Insulin Copay Cap in Medicare
This brief describes the facts about actions taken under both the Trump and Biden Administrations related to capping insulin copayments for people with Medicare and explains the differences between their approaches.
Costly GLP-1 Drugs are Rarely Covered for Weight Loss by Marketplace Plans
Affordable Care Act (ACA) Marketplace plans rarely cover GLP-1 drugs approved solely for obesity treatment, according to a new KFF analysis of 2024 federal plan data. Wegovy, a drug that is approved for weight loss, is covered by just 1% of Marketplace…
Insurer Strategies to Control Costs Associated with Weight Loss Drugs
Affordable Care Act (ACA) Marketplace plans rarely cover GLP-1 drugs approved solely for obesity treatment, according to a an analysis of 2024 federal plan data. Wegovy, a drug that is approved for weight loss, is covered by just 1% of Marketplace pres…
How ACA Marketplace Premiums Changed by County in 2024
This analysis details how ACA marketplace premiums changed by county from 2023 to 2024, after taking into account expanded subsidies available under the Inflation Reduction Act.
